<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>modification_summary_b_032.html</title>
</head>
<body>
<p>* An Ebola virus vaccine program has been added to the clinical development pipeline.</p>
<p>* The RSV vaccine received FDA Fast Track Designation for maternal immunization.</p>
<p>* A Phase 2 clinical trial of the RSV vaccine in elderly adults was initiated.</p>
<p>* The company started a Phase 2 clinical trial of its RSV vaccine in pregnant women.</p>
<p>* A Phase 1 clinical trial for the RSV vaccine in children has been initiated.</p>
<p>* The H7N9 pandemic influenza vaccine was granted FDA Fast Track Designation.</p>
<p>* Positive results were announced from the Phase 1/2 H7N9 pandemic influenza trial.</p>
<p>* A scientific rationale for the VLP vaccine&#x27;s immunological advantages was added.</p>
<p>* The forward-looking statements section was expanded to include additional topics.</p>
<p>* The MERS vaccine program is now explicitly described as a pre-clinical program.</p>
<p>* The joint venture&#x27;s influenza trial completed enrollment and its rabies trial completed.</p>
<p>* HHS BARDA exercised a contract option, adding scope and $70 million in funding.</p>
<p>* A new Ebola virus vaccine program was initiated, including a Phase 1 clinical trial.</p>
<p>* The firm published results showing its MERS vaccine candidate blocked infection in lab studies.</p>
<p>* The CPLB seasonal influenza program completed enrollment for its Phase 3 clinical trial.</p>
<p>* The CPLB rabies program completed enrollment and reported positive initial clinical data.</p>
<p>* The company completed a new public stock offering, raising approximately $108 million.</p>
<p>* A government audit for prior fiscal years was completed with no significant adjustments.</p>
<p>* An Ebola vaccine candidate program was initiated.</p>
<p>* A significant development milestone was triggered under the Wyeth license agreement.</p>
<p>* The company began negotiating to restructure the triggered milestone payment.</p>
<p>* The forward-looking capital sufficiency outlook was shortened to twelve months.</p>
<p>* A significant increase in future capital expenditures is now projected.</p>
<p>* Cash management strategy shifted to purchasing marketable securities for higher returns.</p>
<p>* New contractual obligation categories for milestones and research funding were disclosed.</p>
<p>* The number of research and development employees increased significantly.</p>
<p>* The company&#x27;s final remaining auction rate security was sold.</p>
<p>* The master services agreement with partner Cadila was extended.</p>
<p>* The scope of the Wyeth license was clarified to two influenza programs.</p>
</body>
</html>
